Monday, June 04, 2012

All SharePosts Relating To "In The News"

Dr. Fran Cogen

Dr. Fran Cogen, Health Pro

(Profile)
Director, Child/Adolescent Diabetes Program at Children's Nat'l

Understanding the Risk of Developing Type 1 Diabetes

Damocles was a courtier in the court of Dionysius II of Syracuse in 4th century BC. Unfortunately, Damocles, trying to curry favor, complemented Dionysius by noting that as a "great man of power, he was extremely fortunate." Dionysius offered to trade places with Damocles for a day. In the evening a banquet was held and while Damocles was enjoying... Read moreChevron
posted 08/18/2010, comments (0)|
Dr. Bill Quick

Dr. Bill Quick, Health Pro

(Profile)
Physician who is living with diabetes; editor of www.D-is-for-Diabetes.com

A Dozen Dangerous Supplements

As a physician who has worked in the area of drug safety for many years, I was pleasantly surprised that Consumer Reports, published by Consumers Union (CU), has recently provided a well-reasoned overview of some of the problems with dietary supplements that have irritated me for years. (The article, titled "Dangerous Supplements" is in the... Read moreChevron
Dr. Bill Quick

Dr. Bill Quick, Health Pro

(Profile)
Physician who is living with diabetes; editor of www.D-is-for-Diabetes.com

FDA Advises GSK of Delay in the TIDE Study

This past week, the FDA announced on their website that they had informed GlaxoSmithKline (GSK), the manufacturer of the diabetes drug Avandia (rosiglitazone), that a huge  study  called TIDE (Thiazolidinedione Intervention With Vitamin D Evaluation) "has been placed on partial clinical hold.  Under the partial clinical hold no new... Read moreChevron
posted 07/25/2010, comments (0)|
Dr. Bill Quick

Dr. Bill Quick, Health Pro

(Profile)
Physician who is living with diabetes; editor of www.D-is-for-Diabetes.com

Avandia FDA Advisory Committee Reviews Avandia Warnings

As I mentioned these past two weeks, there was an FDA Advisory Committee (AdComm) meeting on July 13 and 14 that reviewed the safety of the diabetes drug Avandia (rosiglitazone). Transcripts of the sessions will someday be posted at the FDA website, at 2010 Meeting Materials, Endocrinologic and Metabolic Drugs Advisory Committee but until then,... Read moreChevron
Dr. Bill Quick

Dr. Bill Quick, Health Pro

(Profile)
Physician who is living with diabetes; editor of www.D-is-for-Diabetes.com

Avandia Fact Released in Preparation for FDA Hearing

As I mentioned last week, there will be an FDA Advisory Committee (AdComm) meeting this week to discuss the safety of the diabetes drug Avandia (rosiglitazone). The FDA has now published background material in preparation for the meeting, which includes a list of questions that the Advisory Committee will be asked to answer.  To me, the key... Read moreChevron